Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

9 Meters Biopharma Inc (NMTR)

9 Meters Biopharma Inc (NMTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,035
  • Shares Outstanding, K 14,336
  • Annual Sales, $ 0 K
  • Annual Income, $ -43,770 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.36
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.46
  • Most Recent Earnings $-1.02 on 05/15/23
  • Next Earnings Date 08/21/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +124,975.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0715 +0.98%
on 07/25/23
0.7138 -89.89%
on 07/05/23
-0.5988 (-89.24%)
since 06/23/23
3-Month
0.0715 +0.98%
on 07/25/23
1.0700 -93.25%
on 04/26/23
-0.9678 (-93.06%)
since 04/25/23
52-Week
0.0715 +0.98%
on 07/25/23
6.5600 -98.90%
on 08/26/22
-4.5358 (-98.43%)
since 07/25/22

Most Recent Stories

More News
Where Superstar Investor David Tepper Has $5.1 Billion Invested

David Tepper has a stellar investing track record, and here's what he owns now.

MSFT : 429.90 (-0.25%)
QCOM : 161.93 (-0.67%)
INTC : 22.56 (-5.73%)
AMZN : 212.43 (+0.82%)
NVDA : 138.54 (-0.06%)
AMD : 141.56 (-0.35%)
GOOG : 172.76 (-0.13%)
TSM : 195.56 (+0.60%)
FDX : 284.56 (-4.09%)
BABA : 86.01 (+0.07%)
UBER : 72.00 (-1.46%)
NMTR : 0.0722 (-42.97%)
Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

Corium Pharma Solutions, Inc. (“Corium Pharma Solutions” or “CPSI”), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies,...

PG : 177.68 (-1.12%)
AGRX : 1.5100 (unch)
NMTR : 0.0722 (-42.97%)
GNTA : 5.00 (-5.66%)
Pre-Market Brief: Stocks Rebound After Steep Losses

December S&P 500 futures (ESZ22) are trending higher +1.11% this morning after three major US benchmark indices extended declines for the 5th consecutive session as investors continue to fret that higher...

ESZ22 : 3,871.47s (-0.66%)
NEXI.M.DX : 5.688 (-3.69%)
MARA : 24.92 (-2.77%)
HUT : 25.18 (-2.89%)
RIOT : 12.01 (-0.74%)
NMTR : 0.0722 (-42.97%)
ARDS : 0.0001 (unch)
NVDA : 138.54 (-0.06%)
NLS : 0.8204 (+11.20%)
KDP : 32.47 (-0.22%)
SNAP : 12.82 (+5.86%)
9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022

RALEIGH, NC / ACCESSWIRE / July 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced...

NMTR : 0.0722 (-42.97%)
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome

Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel Syndrome

NMTR : 0.0722 (-42.97%)
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

RALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced...

NMTR : 0.0722 (-42.97%)
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation

RALEIGH, NC / ACCESSWIRE / June 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced...

NMTR : 0.0722 (-42.97%)
9 Meters Biopharma to Participate in the 2022 BIO International Convention

RALEIGH, NC / ACCESSWIRE / June 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced...

NMTR : 0.0722 (-42.97%)
9 Meters Biopharma to Exhibit at Digestive Disease Week 2022

RALEIGH, NC / ACCESSWIRE / May 19, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced...

NMTR : 0.0722 (-42.97%)
9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis

RALEIGH, NC / ACCESSWIRE / May 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced...

NMTR : 0.0722 (-42.97%)

Business Summary

9 Meters Biopharma, Inc. is a rare, orphan and unmet needs focused GI company. It's advancing NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for Short Bowel Syndrome, a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported...

See More

Key Turning Points

3rd Resistance Point 0.1406
2nd Resistance Point 0.1267
1st Resistance Point 0.0994
Last Price 0.0722
1st Support Level 0.0582
2nd Support Level 0.0443
3rd Support Level 0.0170

See More

52-Week High 6.5600
Fibonacci 61.8% 4.0814
Fibonacci 50% 3.3158
Fibonacci 38.2% 2.5501
Last Price 0.0722
52-Week Low 0.0715

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar